These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35302625)
1. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2. Chun JY; Jeong H; Kim Y JAMA Netw Open; 2022 Mar; 5(3):e223064. PubMed ID: 35302625 [TBL] [Abstract][Full Text] [Related]
2. Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529). Chun JY; Jeong H; Kim Y BMC Med; 2022 Nov; 20(1):451. PubMed ID: 36419108 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant. Eick-Cost AA; Ying S; Wells N JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453 [TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. Yang W; Shaman J medRxiv; 2021 Nov; ():. PubMed ID: 34845460 [TBL] [Abstract][Full Text] [Related]
6. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. Britton A; Fleming-Dutra KE; Shang N; Smith ZR; Dorji T; Derado G; Accorsi EK; Ajani UA; Miller J; Schrag SJ; Verani JR JAMA; 2022 Mar; 327(11):1032-1041. PubMed ID: 35157002 [TBL] [Abstract][Full Text] [Related]
7. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Nygaard U; Holm M; Hartling UB; Glenthøj J; Schmidt LS; Nordly SB; Matthesen AT; von Linstow ML; Espenhain L Lancet Child Adolesc Health; 2022 Jul; 6(7):459-465. PubMed ID: 35526537 [TBL] [Abstract][Full Text] [Related]
8. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
9. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332 [TBL] [Abstract][Full Text] [Related]
10. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222 [TBL] [Abstract][Full Text] [Related]
12. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536 [TBL] [Abstract][Full Text] [Related]
13. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969 [TBL] [Abstract][Full Text] [Related]
14. Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea. Shim E Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300029 [TBL] [Abstract][Full Text] [Related]
15. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946 [TBL] [Abstract][Full Text] [Related]
16. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC; JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505 [TBL] [Abstract][Full Text] [Related]
17. Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance - Surveillance for Emerging Threats to Pregnant People and Infants. Reeves EL; Neelam V; Carlson JM; Olsen EO; Fox CJ; Woodworth KR; Nestoridi E; Mobley E; Montero Castro S; Dzimira P; Sokale A; Sizemore L; Hall AJ; Ellington S; Cohn A; Gilboa SM; Tong VT Am J Obstet Gynecol MFM; 2024 Feb; 6(2):101265. PubMed ID: 38135220 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study. Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. Tartof SY; Frankland TB; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Aug; 5(8):e2225162. PubMed ID: 35921109 [TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]